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1. Introduction 
Mithramycin is an antitumor antibiotic effective 
against avariety of experimental nd human tumors 
[l-4]. In particular it has been found useful in 
treating human testicular tumors [2,4]. The mecha- 
nism of action of this antibiotic has been investigated 
and it has been shown that the antibiotic binds to DNA 
and inhibits DNA dependent RNA synthesis [S-7]. 
For this drug to bind to DNA, a divalent cation like 
Mg2+ is necessary [7], and mithramycin and other 
structurally related antibiotics like chromomycin A3 
and olivomycin are known to be anionic in nature 
[8]. Nayak et al. [9] have shown that the divalent 
cation is required to counterbalance the electrostatic 
repulsion between the anionic drug and the negatively 
charged phosphate groups of DNA. However, it is 
not clear whether Mg2+ is actually a part of the drug- 
DNA complex or is independent of it. The earlier 
studies indicated that mithramycin does not affect 
the hydrodynamic behaviour of DNA and therefore 
does not bind by intercalation [7-IO]. On the other 
hand, Behr et al. [ 111 have suggested the possibility, 
that chromomycin As, which has a chromophore 
similar to mithramycin, binds by partial intercalation. 
Since the molecular details of binding of mithra- 
mycin to DNA and in particular the role of Mg2+ 
remain unclear, we have examined this question by 
the use of the chelating agent EDTA which chelates 
Mg2+. 
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2. Materials and methods 
DNA was isolated from Yoshida ascites arcoma 
by the method of Kay et al [ 121. The tumor was 
grown in Wistar A/Iisc rats by serial i.p. transplanta- 
tion every fifth day. Mithramycin was a generous gift 
from Pfizer, Maywood, N. J. Spectrophotometric 
titrations were carried out at room temperature (29°C) 
in 0.01 M Tris-HCl buffer, pH 8.0, and spectra were 
recorded by either an Unicam SP 700 or a Carl Zeiss 
VSU-2 spectrophotometer. 
3. Results and discussion 
Addition of Mg2+ to mithramycin produces pec- 
tral changes similar to those produced by DNA in the 
presence of small amounts of Mg”. It was therefore 
necessary to investigate Mg2+-mithramycin interac- 
tion and then evaluate its effect on DNA-mithra- 
mycin complex formation. It was found that high 
concentrations of Mg2+ (in the order of I O-?M) are 
necessary to produce spectral changes imilar in mag- 
nitude to those obtained in DNA-mithramycin inter- 
action (fig.1). The pK~g+ of the Mg2*-mithramycin 
complex was calculated from the concentration-depen- 
dent spectral change and was found to be 3.5 (fig.2). 
It is clear therefore, that at the concentration of Mg2+ 
employed in DNA-mithramycin interactions (Mg’+ 
concentration 15 X lo-‘M) the contribution by the 
Mg*+ towards the observed spectral change is negligi- 
ble. Further, Am of free mithramycin is always 
measured in the presence of magnesium. 
The DNA-mithramycin interaction was studied 
by adding various amounts of DNA to mithramycin 
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Fig.1. Time course of interaction of mithramycin (6.4 X 10m5 M) with Mg” in 0.01 M Tris-HCl buffer, pH 8.0. 
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Fig.2. Change in absorbance of mithramycin (6.4 X lo-* M) 
at 440 nm as a function of Mg” concentration. Tris-HCI 
buffer, 0.01 M, pH 8.0 was used. 
(4.75 X lo-’ M) and Mg2’ (15 X lOUs M) in Tris-HCl 
buffer. The mixture was equilibrated for 30 min at 
room temperature and spectra were recorded. The 
spectral titration curves of a typical experiment are 
shown in fig.3. The spectral changes are similar to 
those observed for chromomycin As [9,13], the absorp- 
tion maximum shifts from 405-440 nm with an iso- 
bestic point at 411 nm. Similar spectral changes also 
occur with DNA- proflavin, DNA-ethidium bromide 
and DNA-actinomycin D interactions for all of which 
intercalation is the preferred mode of binding [ 14-161. 
The association constant of DNA-mithramycin bind- 
ing, calculated from the Scatchard plots of the data, 
is 2 X lo5 M-l. 
The time course of interaction of DNA with mithra- 
mycin is given in tig.4. To check if Mg2+ is actually 
present in the complex, EDTA was added to the 
equilibrated DNA-mithramycin complex and spectral 
changes at 440 nm were recorded. From the time- 
dependent change in absorbance produced by EDTA 
it is clear that rapid dissociation of the complex is 
induced. The half-life of dissociation is 0.7 min as 
against 4.5 min needed for formation of the DNA- 
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A/Mithramycin 
Fig.3. Spectrophotometric titration of mithramycin 
(4.75 X lo-’ M) with Yoshida ascites sarcoma DNA in 
0.01 M Tris-HCl buffer, pH 8.0 and 15 X lo-’ M MgCl,. 
The numbers indicate molar ratio of DNA phosphate to 
mithramycin. 
mithramycin complex. However, addition of EDTA 
to the complex does not produce the spectrum charac- 
teristic of free mithramycin indicating that a fraction 
of the drug probably still remains in the complexed 
form. Higher concentrations of EDTA did not decrease 
the absorbance any further and, much more signifi- 
cantly, EDTA by itself did not induce any changes 
in the spectrum of mithramycin. In contrast, addition 
of EDTA to mithramycin-Mg*’ results in a spectrum 
characteristic of the free drug. It is thus reasonable 
to assume that at the concentrations of EDTA 
employed no Mg*+ will be available for DNA-mithra- 
mycin complex formation. The extent of spectral 
change produced by EDTA indicates that 78% of the 
drug present is dependent on Mg*+ in order to bind 
with DNA. This Mg*+-dependent binding of the drug 
is presumably due to external binding where a diva- 
lent cation is always needed to shield the negative 
charges of anionic mithramycin (pK, = 5) from that 
of the phosphate groups of DNA. 
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Fig.4. Time course of DNA (2.7 X IOF M)-mithramycin 
(5.77 X 10e5 M) complex formation in presence of MgCl, 
(15 X 10e5 M) (a-0); and dissociation of the above complex 
by EDTA (2 X 10“ M) (ad). The titration was carried 
out at 29°C in 0.01 M Tris-HCI buffer, pH 8.0. 
The fraction of the drug that remains complexed 
to DNA even after chelation of Mg*+ is probably 
due to the intercalated form of the drug since no 
divalent cations would be needed for such intercala- 
tion. It is observed that when ethidium bromide, a 
typical intercalating dye, is added to mithramycin- 
DNA, a fraction of the bound drug is displaced. This 
result suggests that a fraction of mithramycin is in 
fact intercalated and it is this intercalated complex 
that is displaced by ethidium bromide. However, it is 
not clear whether Mg *+ is necessary to facilitate the 
entry of the drug to the site of intercalation although 
physico-chemical considerations would require such 
cations in order to overcome the electrostatic repul- 
sion the reactants would intially encounter. 
The complex between mithramycin and DNA, 
which can exist even in the absence of Mg*+, can be 
considered as highly stable, having a relatively slow 
dissociation rate (fig.4). Muller and Crothers have 
suggested that in the case of such complexes dissocia- 
tion rates are more important than association rates 
in determining the biological activity of the drug [ 161; 
that is, a slower dissociation of the complex implies 
a higher biological activity. It follows then that it is 
the Mg*+-independent DNA-mithramycin complex 
(which presumably has mithramycin in an intercalated 
form) which is largely responsible for the observed 
inhibition of transcription. 
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